Luxturna Approval History
FDA Approved: Yes (First approved December 19, 2017)
Brand name: Luxturna
Generic name: voretigene neparvovec
Dosage form: Intraocular Suspension for Subretinal Injection
Company: Spark Therapeutics, Inc.
Treatment for: Biallelic RPE65-Mediated Inherited Retinal Disease
Luxturna (voretigene neparvovec) is an adeno-associated viral (AAV) vector gene therapy for the treatment of patients with vision loss due to confirmed biallelic RPE65-mediated inherited retinal disease (IRD).